Nielsen BioSciences controls the candin market as hospitals drive demand

The Business Research Company says Nielsen BioSciences held 100% of global candin sales in 2025, while hospitals accounted for 61% of demand. The report points to steady growth through 2030 as antifungal diagnostics and immunotherapy-based uses expand.

Why it matters: - The candin market is small, but it sits at the intersection of antifungal diagnostics, immune testing and invasive fungal infection care. - The market’s growth matters most for hospitals, specialty clinics and patients with weakened immune systems who need faster, more precise testing. - The report forecasts the market will stay niche even as demand rises, which highlights how concentrated and regulated the segment remains.

What happened: - The Business Research Company projected the candin market will exceed $0.005 billion by 2030. - Nielsen BioSciences Inc. held 100% of global candin sales in 2025, according to the report. - Hospitals represented 61% of market demand in 2030, or about $0.003 billion. - North America is projected to be the largest regional market in 2030 at $0.0039 billion. - The United States is expected to remain the largest country market at $0.0038 billion in 2030.

The details: - The report puts 2025 global candin market revenue at Nielsen BioSciences alone, describing the market as moderately fragmented despite that concentration. - Barriers to entry include strict pharmaceutical quality requirements, complex drug development and regulatory approval hurdles. - The market is forecast to grow at a 5% compound annual growth rate through 2030. - The candin market is a tiny slice of the broader dermatology drugs market, which is forecast to reach about $97 billion by 2030. - Within the larger pharmaceuticals industry, the report says candin will account for about 0.0002% by 2030. - Product use is centered on hospitals and specialty clinics. - Patient groups include immunocompromised patients, infectious disease and HIV/AIDS patients, and pediatric and geriatric groups. - Indications include candidiasis and thrush. - Distribution runs through hospital pharmacies, retail pharmacies and online pharmacies. - The report lists Candin as a skin test antigen used to evaluate cell-mediated immunity and delayed hypersensitivity. - The report says rising fungal infections, an aging population, diabetes, prolonged antibiotic use, cancer treatment and organ transplants are increasing the pool of at-risk patients. - That trend is expected to add about 1.5% annual growth to the market. - Expanding immunocompromised populations are projected to contribute about 1.0% annual growth. - Increasing use of minimally invasive diagnostic skin tests is expected to add roughly 0.8% annual growth. - Hospitals are favored because they have trained staff, inpatient care for vulnerable patients, established pharmacy procurement systems and clinical pathways for invasive fungal infections. - The report says hospitals and specialty clinics together could add more than $0.002 billion in market value by 2030. - Each of those segments is projected to grow by about $0.001 billion between 2025 and 2030. - The supply chain includes raw material suppliers such as Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, Lonza, Sartorius and Fujifilm Irvine Scientific. - The report also names McKesson, Cardinal Health, Cencora, Henry Schein, Medline and Owens & Minor as wholesalers and distributors. - End users include Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Stanford Health Care, UCSF Health, Memorial Sloan Kettering Cancer Center, Mount Sinai Health System, Kaiser Permanente, HCA Healthcare and Quest Diagnostics.

Between the lines: - The market’s concentration around a single seller suggests a narrow commercial base, even as clinical use cases broaden. - The growth outlook appears to depend more on diagnostic demand and specialty care settings than on mass-market drug adoption. - Nielsen BioSciences’ Phase 3 CANDIN data for common wart treatment in May 2026 signals a potential expansion beyond skin testing, if regulators and clinicians follow through. - The report’s emphasis on hospital use suggests adoption is tied to institutional purchasing and clinical protocols rather than retail demand.

What's next: - Nielsen BioSciences will likely seek to convert its Phase 3 trial results into regulatory progress for CANDIN in wart treatment. - The report expects strategic partnerships, product innovation, clinical advances and geographic expansion to shape the next phase of competition. - Growth is likely to remain modest in absolute dollar terms, even if demand for fungal infection management keeps rising.

The bottom line: - Candin is a tiny market with one dominant supplier, but rising fungal infection risk and hospital-based diagnostic use could keep it growing through 2030.

More information: Request a free sample of the Candin market report - Access the detailed Candin market report - The Business Research Company